Cancer Biomarkers Market Hits US$ 20.48 Billion by 2022 - Top Technologies, Overview, Key Insights and Company Profiles

Cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period.

Report also offers market sizes and data on the growth of various segments of industry. It focuses on emerging and high-growth segments, and high-growth regions. Competitive landscape covers growth strategies adopted by industry players in last three years. Company profiles comprise basic views on key players in cancer biomarkers market & product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in near future.

Cancer Biomarkers Market Research Sample Papers Available Now at https://www.reportsnreports.com/contacts/requestsample.aspx?name=420487 .

The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022. Over years, cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies.

North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017.The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Target Audience Covered are Manufacturing companies of diagnostics kits and imaging instrument providers, Biomarkers assay and reagent manufacturers, vendors, and distributors, Contract research organizations (CROs), Companies offering platforms/technologies for cancer diagnosis, Market research and consulting firms, and Venture capitalists and investors.

Get 15% Discount on “Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022” report at https://www.reportsnreports.com/contacts/discount.aspx?name=420487 .

Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

Scope of the Report
• The market study doesn’t cover the market size in terms of volume
• Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
• Company developments not reported in the public domain are not included in this report

Get Free Assistance Now at Call +1 888 391 5441 / sales@reportsandreports.com .

We provides you the further information and more details with intelligence needs for your business. Access to in-depth market trends helps companies to assess the market effectiveness.

With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.